PIEZO1 and myeloid sarcoma: After Piezo1 are activated, they inhibit TGFβ/SMAD signaling pathway in CD4+ T cells and restrain Treg activity (70), which impairs the ability of Treg cells to suppress autoreactive effector T cells in MS/EAE (71).